pfizer glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option Pfizer's monthly obesity injection drove

Gorski JA, Balogh SA, Wehner JM, Jones KR (2003a)

Get daily sunlight

60 These findings are supported by additional observational and real-world cohort studies demonstrating similar pancreatitis rates among patients treated with GLP-1 RAs and those receiving other glucose-lowering therapies

As most patients with type 2 diabetes are treated in the primary-care setting, the increasing utilization of SGLT2 inhibitors and GLP1 agonists by our primary-care colleagues will improve outcomes in people with type 2 diabetes on a population level. The clinical guidelines cautioned against treating people with type 2 diabetes with inadequate glycemic control with dipeptidyl peptidase-4 (DPP-4) inhibitors, saying that high-certainty evidence showed that adding a DPP-4 inhibitor does not reduce morbidity or all-cause mortality.

Clin Lab 64(1):5967